Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by TAPAN MAHENDRA KADIA and ZEEV ESTROV.
TAPAN MAHENDRA KADIA
Connection Strength
4.049
ZEEV ESTROV
  1. Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2021 08 01; 96(8):914-924.
    View in: PubMed
    Score: 0.196
  2. Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. Cancer. 2021 06 01; 127(11):1894-1900.
    View in: PubMed
    Score: 0.191
  3. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer. 2018 11 01; 124(21):4192-4201.
    View in: PubMed
    Score: 0.163
  4. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol. 2018 Sep; 5(9):e411-e421.
    View in: PubMed
    Score: 0.162
  5. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv. 2017 Jul 25; 1(17):1312-1323.
    View in: PubMed
    Score: 0.150
  6. Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). Ann Oncol. 2017 Jul 01; 28(7):1554-1559.
    View in: PubMed
    Score: 0.150
  7. TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer. 2016 Nov 15; 122(22):3484-3491.
    View in: PubMed
    Score: 0.140
  8. Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2015 Feb; 90(2):120-4.
    View in: PubMed
    Score: 0.125
  9. Central nervous system Richter's transformation and parvovirus B19 infection. Leuk Lymphoma. 2013 Sep; 54(9):2070-2.
    View in: PubMed
    Score: 0.111
  10. Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol. 2012 May; 157(3):312-20.
    View in: PubMed
    Score: 0.103
  11. Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study. Haematologica. 2024 08 01; 109(8):2660-2664.
    View in: PubMed
    Score: 0.061
  12. A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma. 2022 09; 63(9):2161-2170.
    View in: PubMed
    Score: 0.052
  13. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv. 2021 08 24; 5(16):3163-3173.
    View in: PubMed
    Score: 0.050
  14. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol. 2021 Aug 01; 7(8):1213-1219.
    View in: PubMed
    Score: 0.050
  15. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica. 2021 08 01; 106(8):2121-2130.
    View in: PubMed
    Score: 0.050
  16. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia. 2021 12; 35(12):3421-3429.
    View in: PubMed
    Score: 0.049
  17. Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study. Clin Infect Dis. 2021 05 18; 72(10):1755-1763.
    View in: PubMed
    Score: 0.049
  18. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer. 2021 09 01; 127(17):3113-3124.
    View in: PubMed
    Score: 0.049
  19. Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. Blood Adv. 2021 04 27; 5(8):2156-2164.
    View in: PubMed
    Score: 0.049
  20. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia. 2021 05; 35(5):1494-1499.
    View in: PubMed
    Score: 0.049
  21. Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. Am J Hematol. 2021 02 01; 96(2):E50-E53.
    View in: PubMed
    Score: 0.047
  22. Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis. Leuk Lymphoma. 2021 01; 62(1):224-228.
    View in: PubMed
    Score: 0.047
  23. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020 Oct; 7(10):e724-e736.
    View in: PubMed
    Score: 0.047
  24. Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. Am J Hematol. 2020 11; 95(11):1288-1295.
    View in: PubMed
    Score: 0.046
  25. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia. 2020 11; 34(11):2914-2924.
    View in: PubMed
    Score: 0.046
  26. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia. 2020 09; 34(9):2489-2492.
    View in: PubMed
    Score: 0.045
  27. Long-term results of frontline dasatinib in chronic myeloid leukemia. Cancer. 2020 04 01; 126(7):1502-1511.
    View in: PubMed
    Score: 0.045
  28. Long-term results of a phase 2 trial of nilotinib 400?mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia. Cancer. 2020 04 01; 126(7):1448-1459.
    View in: PubMed
    Score: 0.045
  29. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol. 2020 02; 95(2):144-150.
    View in: PubMed
    Score: 0.044
  30. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol. 2019 Sep; 6(9):e480-e488.
    View in: PubMed
    Score: 0.043
  31. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019 05 30; 380(22):2095-2103.
    View in: PubMed
    Score: 0.043
  32. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv. 2019 03 26; 3(6):851-861.
    View in: PubMed
    Score: 0.042
  33. Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia? Blood Cancer J. 2019 01 16; 9(2):7.
    View in: PubMed
    Score: 0.042
  34. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol. 2019 Jan; 6(1):e29-e37.
    View in: PubMed
    Score: 0.041
  35. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019 03 07; 133(10):1011-1019.
    View in: PubMed
    Score: 0.041
  36. A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. Cancer Med. 2018 11; 7(11):5457-5469.
    View in: PubMed
    Score: 0.041
  37. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 10 18; 132(16):1664-1674.
    View in: PubMed
    Score: 0.041
  38. Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. Am J Hematol. 2018 09; 93(9):1136-1141.
    View in: PubMed
    Score: 0.041
  39. MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma. 2019 01; 60(1):37-48.
    View in: PubMed
    Score: 0.040
  40. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia. 2018 11; 32(11):2388-2398.
    View in: PubMed
    Score: 0.040
  41. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2018 07 01; 124(13):2758-2765.
    View in: PubMed
    Score: 0.040
  42. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. JAMA Oncol. 2018 Feb 01; 4(2):230-234.
    View in: PubMed
    Score: 0.039
  43. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget. 2018 Feb 09; 9(11):9714-9727.
    View in: PubMed
    Score: 0.039
  44. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol. 2018 02; 93(2):277-285.
    View in: PubMed
    Score: 0.038
  45. Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. Cancer. 2017 Dec 15; 123(24):4851-4859.
    View in: PubMed
    Score: 0.038
  46. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood. 2017 09 28; 130(13):1514-1522.
    View in: PubMed
    Score: 0.038
  47. Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens. Am J Hematol. 2017 10; 92(10):E595-E597.
    View in: PubMed
    Score: 0.038
  48. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer. 2017 Nov 15; 123(22):4391-4402.
    View in: PubMed
    Score: 0.038
  49. Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. Am J Hematol. 2017 Sep; 92(9):924-928.
    View in: PubMed
    Score: 0.038
  50. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2018 04; 59(4):813-820.
    View in: PubMed
    Score: 0.038
  51. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer. 2017 Nov 15; 123(22):4430-4439.
    View in: PubMed
    Score: 0.037
  52. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. Cancer. 2017 Oct 01; 123(19):3717-3724.
    View in: PubMed
    Score: 0.037
  53. An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes. Am J Hematol. 2017 Jul; 92(7):674-682.
    View in: PubMed
    Score: 0.037
  54. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. Am J Hematol. 2017 Jul; 92(7):599-606.
    View in: PubMed
    Score: 0.037
  55. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. 2017 07; 31(7):1659.
    View in: PubMed
    Score: 0.037
  56. Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents. Am J Hematol. 2017 Apr; 92(4):351-358.
    View in: PubMed
    Score: 0.036
  57. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017 03 09; 129(10):1275-1283.
    View in: PubMed
    Score: 0.036
  58. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. 2017 02; 31(2):318-324.
    View in: PubMed
    Score: 0.036
  59. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer. 2017 02 01; 123(3):426-435.
    View in: PubMed
    Score: 0.035
  60. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget. 2016 Mar 22; 7(12):14172-87.
    View in: PubMed
    Score: 0.034
  61. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood. 2016 Mar 10; 127(10):1269-75.
    View in: PubMed
    Score: 0.034
  62. Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):163-8.e1-2.
    View in: PubMed
    Score: 0.033
  63. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2016 Feb; 172(3):392-400.
    View in: PubMed
    Score: 0.033
  64. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015 Nov; 16(15):1547-1555.
    View in: PubMed
    Score: 0.033
  65. Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol. 2015 Apr; 90(4):276-81.
    View in: PubMed
    Score: 0.032
  66. Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor. Leuk Lymphoma. 2015 Apr; 56(4):1012-9.
    View in: PubMed
    Score: 0.031
  67. A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2014 Oct; 14(5):401-10.
    View in: PubMed
    Score: 0.030
  68. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients =60 years with newly diagnosed acute myeloid leukemia. Am J Hematol. 2013 Nov; 88(11):961-6.
    View in: PubMed
    Score: 0.029
  69. Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. Am J Hematol. 2013 Oct; 88(10):831-7.
    View in: PubMed
    Score: 0.028
  70. Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am J Hematol. 2013 May; 88(5):365-9.
    View in: PubMed
    Score: 0.028
  71. Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation. Leukemia. 2013 Apr; 27(4):836-42.
    View in: PubMed
    Score: 0.027
  72. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012 Aug 09; 120(6):1202-9.
    View in: PubMed
    Score: 0.026
  73. Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 2012 Jun; 12(3):197-200.
    View in: PubMed
    Score: 0.026
  74. Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. Am J Hematol. 2012 Jan; 87(1):127-9.
    View in: PubMed
    Score: 0.025
  75. Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. J Clin Oncol. 2011 Jun 20; 29(18):2507-13.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.